EARLY PDD CYSTOSCOPY AFTER BCG INDUCTION INCREASES DETECTION OF BCG-REFRACTORY TUMORS

被引：0
|
作者：
Morelli, Michele [1 ]
Baboudjian, Michael [1 ]
Tadrist, Abel [1 ]
Gondran-tellier, Bastien [1 ]
Karsenty, Gilles [1 ]
Lechevallier, Eric [1 ]
Montanari, Emanuele [2 ]
Boissier, Romain [1 ]
机构：
[1] Conception Hosp, AP HM, Dept Urol & Kidney Transplantat, Marseilles, France
[2] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dept Urol, Milan, Italy
来源：
ANTICANCER RESEARCH | 2021年 / 41卷 / 10期
关键词：
D O I：
10.21873/anticanres.15345
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1
引用
下载
收藏
页码：5259 / 5259
页数：1
相关论文
共 50 条
  • [21] Risk of continued intravesical therapy and delayed cystectomy in BCG-refractory superficial bladder cancer: An investigational approach
    Luciani, LG
    Neulander, E
    Murphy, WM
    Wajsman, Z
    UROLOGY, 2001, 58 (03) : 376 - 379
  • [22] INDUCTION AND EXPRESSION OF IMMUNITY AFTER BCG IMMUNIZATION
    LEFFORD, MJ
    INFECTION AND IMMUNITY, 1977, 18 (03) : 646 - 653
  • [23] Is gemcitabine an option in BCG-refractory nonmuscle-invasive bladder cancer? A single-arm prospective trial
    Perdona, Sisto
    Di Lorenzo, Giuseppe
    Cantiello, Francesco
    Damiano, Rocco
    De Sio, Marco
    Masala, Daniele
    Bruni, Gianni
    Gallo, Luigi
    Federico, Piera
    Quattrone, Carmelo
    Pizzuti, Mariano
    Autorino, Riccardo
    ANTI-CANCER DRUGS, 2010, 21 (01) : 101 - 106
  • [24] Investigation of the causes of BCG refractory in patients treated with intracavitary BCG as secondary treatment in superficial bladder tumors with transurethral resection
    Yorulmaz, Enis Mert
    Yilmaz, Yuksel
    Kose, Osman
    Akin, Yigit
    Gorgel, Sacit Nuri
    Ozcan, Serkan
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2022, 54 (03) : 533 - 540
  • [25] Investigation of the causes of BCG refractory in patients treated with intracavitary BCG as secondary treatment in superficial bladder tumors with transurethral resection
    Enis Mert Yorulmaz
    Yüksel Yılmaz
    Osman Köse
    Yiğit Akın
    Sacit Nuri Görgel
    Serkan Özcan
    International Urology and Nephrology, 2022, 54 : 533 - 540
  • [26] Phase I clinical trial of external hyperthermia and intravesical mitomycin C to treat BCG-refractory bladder cancer.
    Abern, Michael
    Vujaskovic, Zeljko
    Dewhirst, Mark W.
    Lan, Lan
    Craciunescu, Oana I.
    Stauffer, Paul
    Inman, Brant Allen
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [27] PATHOLOGIC UPSTAGING AT THE TIME OF RADICAL CYSTECTOMY IS ASSOCIATED WITH WORSE RECURRENCE FREE SURVIVAL IN PATIENTS WITH BCG-REFRACTORY BLADDER CANCER
    Guzzo, Thomas J.
    Magheli, Ahmed
    Bivalacqua, Trinity J.
    Nielsen, Matthew E.
    Attenello, Frank
    Ball, Mark W.
    Schoenberg, Mark P.
    Gonzalgo, Mark L.
    JOURNAL OF UROLOGY, 2009, 181 (04): : 641 - 641
  • [28] Intravesical gemcitabine in BCG-refractory T1G3 transitional cell carcinoma of the bladder: A pilot study
    Gacci, M
    Bartoletti, R
    Cai, T
    Nerozzi, S
    Pinzi, N
    Repetti, F
    Viggiani, F
    Ghezzi, P
    Nesi, G
    Carini, M
    UROLOGIA INTERNATIONALIS, 2006, 76 (02) : 106 - 111
  • [29] Efficacy of hyperthermic-intra-vesical chemotherapy in patients with BCG-refractory nonmuscle-invasive bladder cancer.
    Pignot, Geraldine
    Lorusso, Vito
    Doisy, Laure
    Guerin, Mathilde
    Vicier, Cecile
    Dermeche, Slimane
    Branger, Nicolas
    Maubon, Thomas
    Rybikowski, Stanislas
    Walz, Jochen
    Gravis, Gwenaelle
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [30] REGRESSION OF ESTABLISHED ORAL TUMORS AFTER INTRA-LESIONAL INJECTION OF LIVING BCG OR BCG CELL-WALLS
    ZBAR, B
    CANTI, G
    RAPP, HJ
    BIER, J
    BORSOS, T
    CANCER, 1979, 43 (04) : 1304 - 1307
12345